{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-07T00:16:13.815548+00:00","company":{"ticker":"FHTX","cik":1822462,"company_name":"Foghorn Therapeutics Inc."},"pagination":{"limit":100,"returned":9,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"01da4ed373bdc710440991ec73b518fb5cd860c8","cik":1822462,"ticker":"FHTX","company_name":"Foghorn Therapeutics Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":null},"claim":"Foghorn Therapeutics Inc. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"On May 7, 2026, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-031669","anchor_url":"https://secwatch.observer/filing/0001628280-26-031669#claim-01da4ed373bdc710440991ec73b518fb5cd860c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828026031669/0001628280-26-031669-index.htm"},{"fact_type":"executive_change","fact_key":"9ccea0da50","cik":1822462,"ticker":"FHTX","company_name":"Foghorn Therapeutics Inc.","filed_at":"2025-05-01T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-05-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Neil J. Gallagher was appointed as Director at Foghorn Therapeutics Inc..","evidence_excerpt":"appointed Neil J. Gallagher, M.D., Ph.D. to the Board, effective May 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-25-021506","anchor_url":"https://secwatch.observer/filing/0001628280-25-021506#claim-9ccea0da50","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025021506/0001628280-25-021506-index.htm"},{"fact_type":"executive_change","fact_key":"d535e86da6","cik":1822462,"ticker":"FHTX","company_name":"Foghorn Therapeutics Inc.","filed_at":"2025-05-01T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-05-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Stuart Duty was appointed as Director at Foghorn Therapeutics Inc..","evidence_excerpt":"appointed Stuart Duty to the Board, effective May 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-25-021506","anchor_url":"https://secwatch.observer/filing/0001628280-25-021506#claim-d535e86da6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025021506/0001628280-25-021506-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"fae198e41a88bc8bd9db191c9b5c338a769a06e1","cik":1822462,"ticker":"FHTX","company_name":"Foghorn Therapeutics Inc.","filed_at":"2025-01-24T23:59:59+00:00","payload":{"company_response":"Board intends to appoint a new or existing independent Board member to the Audit Committee and expects to be compliant by the end of the cure period.","compliance_status":"deficient","cure_deadline":"2025-12-29","deficiency_type":"audit_committee","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-01-23","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":[]},"claim":"Foghorn Therapeutics Inc. received a nasdaq deficiency notice notice regarding audit committee.","evidence_excerpt":"January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-25-002466","anchor_url":"https://secwatch.observer/filing/0001628280-25-002466#claim-fae198e41a88bc8bd9db191c9b5c338a769a06e1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/0001628280-25-002466-index.htm"},{"fact_type":"earnings_release","fact_key":"92939d00dbf1681e24c9355e52d2a0a1b2c4ffc3","cik":1822462,"ticker":"FHTX","company_name":"Foghorn Therapeutics Inc.","filed_at":"2024-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-06","result_type":"reported_results","revenue_text":null},"claim":"Foghorn Therapeutics Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 6, 2024, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-020454","anchor_url":"https://secwatch.observer/filing/0001628280-24-020454#claim-92939d00dbf1681e24c9355e52d2a0a1b2c4ffc3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024020454/0001628280-24-020454-index.htm"},{"fact_type":"executive_change","fact_key":"851ff817a4","cik":1822462,"ticker":"FHTX","company_name":"Foghorn Therapeutics Inc.","filed_at":"2024-04-16T23:59:59+00:00","payload":{"action":"ceased to serve","action_category":"departure","departure_tone":"routine","effective_date":"2024-04-16","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":"Kristian F. Humer","successor_named":true},"claim":"Stephen DiPalma departed as Interim Chief Financial Officer at Foghorn Therapeutics Inc..","evidence_excerpt":"In connection with Mr. Humer’s appointment, Stephen DiPalma, the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, will cease to serve in such roles.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001628280-24-016281","anchor_url":"https://secwatch.observer/filing/0001628280-24-016281#claim-851ff817a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024016281/0001628280-24-016281-index.htm"},{"fact_type":"executive_change","fact_key":"951836ee12","cik":1822462,"ticker":"FHTX","company_name":"Foghorn Therapeutics Inc.","filed_at":"2024-04-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-04-16","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Kristian F. Humer was appointed as Chief Financial Officer at Foghorn Therapeutics Inc..","evidence_excerpt":"On April 16, 2024, Foghorn Therapeutics Inc. (the “Company”) announced that Kristian F. Humer had been appointed to serve as the Company’s Chief Financial Officer, effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001628280-24-016281","anchor_url":"https://secwatch.observer/filing/0001628280-24-016281#claim-951836ee12","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024016281/0001628280-24-016281-index.htm"},{"fact_type":"earnings_release","fact_key":"1a2704f9fad837fefb49aa7d9b8eca64779cd94a","cik":1822462,"ticker":"FHTX","company_name":"Foghorn Therapeutics Inc.","filed_at":"2024-03-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the year ended December 31, 2023","report_date":"2024-03-07","result_type":"reported_results","revenue_text":"$34.2 million"},"claim":"Foghorn Therapeutics Inc. reported the year ended December 31, 2023 results: revenue $34.2 million.","evidence_excerpt":"three discovery programs using Foghorn’s proprietary Gene Traffic Control platform. Full Year 2023 Financial Highlights • Collaboration Revenues . Collaboration revenues were $34.2 million for the year ended December 31, 2023, compared to $19.2 million for the year ended December 31, 2022. The increase year-over-year was primarily driven by revenue recognized under","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001628280-24-009540","anchor_url":"https://secwatch.observer/filing/0001628280-24-009540#claim-1a2704f9fad837fefb49aa7d9b8eca64779cd94a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024009540/0001628280-24-009540-index.htm"},{"fact_type":"executive_change","fact_key":"871c884efb","cik":1822462,"ticker":"FHTX","company_name":"Foghorn Therapeutics Inc.","filed_at":"2024-01-17T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-16","interim":true,"role":"Treasurer and interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Stephen J. DiPalma was appointed as Treasurer and interim Chief Financial Officer at Foghorn Therapeutics Inc..","evidence_excerpt":"On January 16, 2024, the Board of Directors of Foghorn Therapeutics Inc. (the “Company”) appointed Stephen J. DiPalma as Treasurer and interim Chief Financial Officer (“CFO”), effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-001504","anchor_url":"https://secwatch.observer/filing/0001628280-24-001504#claim-871c884efb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024001504/0001628280-24-001504-index.htm"}]}